---
id: aan-migraine-prevention-2024
title: "AAN 2024 Practice Guideline Update: Preventive Treatment of Migraine in Adults"
short_title: "AAN Migraine Prevention 2024"

organization: American Academy of Neurology
collaborators:
  - American Headache Society
country: US
url: https://www.aan.com/Guidelines/
doi: null
pmid: null
open_access: true

specialty: neurology
guideline_type: clinical-practice
evidence_system: AAN
conditions:
  - migraine
  - chronic migraine
  - episodic migraine
tags:
  - CGRP inhibitors
  - topiramate
  - propranolol
  - botulinum toxin
  - headache diary

publication_date: 2024-04-01
previous_version_date: 2021-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 AAN/AHS practice guideline update on pharmacologic and non-pharmacologic preventive treatment of migraine in adults.

## Key Recommendations

### When to Consider Prevention
- ≥4 migraine days per month.
- Significant disability despite acute treatment.
- Contraindication to or overuse of acute medications.
- Patient preference for prevention.

### Traditional Oral Preventives

#### Established Efficacy (Level A)
- **Propranolol, Metoprolol**: Beta-blockers.
- **Topiramate**: Antiepileptic; side effects (cognitive, weight loss).
- **Valproate**: Antiepileptic; avoid in pregnancy.
- **Amitriptyline**: TCA; useful for comorbid insomnia or depression.

#### Probable Efficacy (Level B)
- **Venlafaxine**: SNRI.
- **Candesartan**: ARB.

### CGRP Pathway Monoclonal Antibodies (mAbs)
- **Erenumab (Aimovig)**, **Fremanezumab (Ajovy)**, **Galcanezumab (Emgality)**, **Eptinezumab (Vyepti)**.
- Highly effective, well-tolerated, monthly or quarterly dosing.
- May be considered early in treatment algorithm, especially if traditional preventives are contraindicated, ineffective, or not tolerated.

### OnabotulinumtoxinA (Botox)
- Approved for chronic migraine (≥15 headache days/month, ≥8 migraine days).
- Injections every 12 weeks.

### Small Molecule CGRP Receptor Antagonists (Gepants for Prevention)
- **Atogepant (Qulipta)**, **Rimegepant (Nurtec ODT – dual acute/preventive)**: Oral CGRP receptor antagonists approved for episodic and chronic migraine prevention.

### Non-Pharmacologic
- Behavioral therapies (CBT, biofeedback, relaxation).
- Regular sleep, exercise, hydration.
- Trigger avoidance.
- Neuromodulation devices (sTMS, eTNS, nVNS) for select patients.

### Approach
- Start one preventive at low dose; titrate slowly.
- Assess efficacy over 2-3 months; maintain headache diary.
